Last reviewed · How we verify

GSK573719/GW642444 125/25 — Competitive Intelligence Brief

GSK573719/GW642444 125/25 (GSK573719/GW642444 125/25) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LAMA/LABA combination. Area: Respiratory.

phase 3 LAMA/LABA combination Muscarinic M3 receptor / Beta-2 adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

GSK573719/GW642444 125/25 (GSK573719/GW642444 125/25) — GlaxoSmithKline. GSK573719/GW642444 is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GSK573719/GW642444 125/25 TARGET GSK573719/GW642444 125/25 GlaxoSmithKline phase 3 LAMA/LABA combination Muscarinic M3 receptor / Beta-2 adrenergic receptor
GSK573719/GW642444 Inhalation Powder GSK573719/GW642444 Inhalation Powder GlaxoSmithKline phase 3 LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) M3 muscarinic receptor; beta-2 adrenergic receptor
Triple FF/UMEC/VI Triple FF/UMEC/VI GlaxoSmithKline phase 3 ICS/LAMA/LABA combination Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
LAMA/LABA LAMA/LABA Queen's University phase 3 LAMA/LABA combination bronchodilator Muscarinic M3 receptor and beta-2 adrenergic receptor
GSK573719/VI 125/25 GSK573719/VI 125/25 GlaxoSmithKline phase 3 LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) M3 muscarinic receptor and beta-2 adrenergic receptor
Glycopyrronium/Formoterol Fumarate Glycopyrronium/Formoterol Fumarate AstraZeneca phase 3 LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist) Muscarinic M3 receptor; Beta-2 adrenergic receptor
GSK573719 + GW642444 62.5/25 GSK573719 + GW642444 62.5/25 GlaxoSmithKline phase 3 Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination) M3 muscarinic receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LAMA/LABA combination class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK573719/GW642444 125/25 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk573719-gw642444-125-25. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: